Form 8-K - Current report:
SEC Accession No. 0001933414-25-000057
Filing Date
2025-05-12
Accepted
2025-05-12 16:13:55
Documents
15
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mlys-20250512.htm   iXBRL 8-K 27291
2 EX-99.1 mlys2025q18kex991.htm EX-99.1 65921
6 a1a.jpg GRAPHIC 5244
  Complete submission text file 0001933414-25-000057.txt   243301

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mlys-20250512.xsd EX-101.SCH 1794
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mlys-20250512_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mlys-20250512_pre.xml EX-101.PRE 13589
17 EXTRACTED XBRL INSTANCE DOCUMENT mlys-20250512_htm.xml XML 2929
Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Filer) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41614 | Film No.: 25934986
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)